HighTide Therapeutics, Inc. Overview
Pro stress-test →HighTide Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. The company's lead drug candidate HTD1801 has successfully completed Phase III clinical trials in patients with type 2 diabetes, demonstrating efficacy and safety advantages over 52 weeks.
Strategic Profile
Pro stress-test →HighTide's lead compound, berberine ursodeoxycholate (HTD1801), is a potential first-in-class therapeutic for NASH, type 2 diabetes, severe hypertriglyceridemia, and cholangitis, with Fast Track designation for NASH and PSC and Orphan Drug designation for PSC from the US FDA. The company is pursuing multi-regional clinical development with support from Hong Kong's biotech ecosystem.
Competitive Landscape
Pro stress-test →HighTide operates in a fragmented orphan/specialty pharma market competing against both multinational pharmaceuticals (Gilead Sciences in PSC research) and emerging biotech firms. The PSC market includes competitors such as Chemomab Therapeutics, Dr. Falk Pharma, Escient Pharmaceuticals, and Mirum Pharmaceuticals. HighTide's competitive advantage lies in first-in-class positioning for HTD1801 and multi-indication development strategy.
Industry Context
HighTide Therapeutics, Inc. operates in Biopharmaceutical Manufacturing & Drug Development (Specialty Pharma).
Key facts
Founded: 2011 · Headquarters: Shenzhen, China · Employees: 70 · Revenue: N/A (pre-commercialization) · Market cap: $2.23B HKD